# Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct07225621/  
OnCo record `nct07225621` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Alpheus Medical, Inc., now recruiting.

## Summary

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma is a phase 2 interventional study registered as NCT07225621 by Alpheus Medical, Inc., with 103 participants planned, started 2026-01-28 and due to reach its primary completion in 2027-12. Interventions recorded: 5-ALA HCl + LIDU SDT and Placebo + Sham SDT.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07225621
- Phase: 2
- Setting: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Comparing Standard of Care Adjuvant Temozolomide With or Without 5-Aminolevulinic Acid (5-ALA) With Concomitant Low Intensity Diffuse Ultrasound (LIDU) Sonodynamic Therapy (SDT) System In Patients With Newly Diagnosed Glioblastoma After Completion of Chemoradiotherapy
- Sponsor: Alpheus Medical, Inc.
- Enrolled: 103

## Sources

- ClinicalTrials.gov NCT07225621: https://clinicaltrials.gov/study/NCT07225621

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Aminolevulinic acid (topical, for photodynamic therapy)](https://onco.cc/drugs/aminolevulinic-acid/)

---
JSON: https://onco.cc/api/v1/entities/nct07225621.json